FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Side-by-side placement of fully covered metal stents versus conventional 7F plastic stents in malignant hilar biliary obstruction: Prospective randomized controlled trial. PMID 37612129 · Dig Endosc · 2024-Apr 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Robot-assisted Simple Enucleation Versus Standard Robot-assisted Partial Nephrectomy for Low- or Intermediate-complexity, Clinical T1 Renal Tumors: A Randomized Controlled Noninferiority Trial. PMID 37598032 · Eur Urol Oncol · 2024-Apr The record describes a randomized surgical trial for renal cancer with a primary endpoint of surgical margin status. While it is an oncology trial with human subjects and a randomized design, it lacks the required drug intervention and a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) with Kaplan-Meier or HR reporting. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Partially covered versus uncovered pyloro-duodenal stents for unresectable malignant gastric outlet obstruction: Randomized controlled study. PMID 37522554 · Dig Endosc · 2024-Apr 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Can an Integrated Palliative and Oncology Co-rounding Model Reduce Aggressive Care at the End of Life? Secondary Analysis of an Open-label Stepped-wedge Cluster-randomized Trial. PMID 37246153 · Am J Hosp Palliat Care · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Oxidized Regenerated Cellulose Versus Calcium Alginate in Controlling Bleeding From Malignant Wounds: A Randomized Controlled Trial. PMID 37058598 · Cancer Nurs · 2024 Sep The record is excluded because it does not meet the required drug-intervention criterion; it is a study of hemostatic dressings, not a drug. The phase is also not established as definitively Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of a Protocol Intervention for Aspiration Pneumonia Prevention in Patients With Esophageal Cancer During Concurrent Chemoradiotherapy: A Randomized Control Trial. PMID 36696534 · Cancer Nurs · 2024 Jul While the study is an oncology RCT reporting a time-to-event outcome (survival time), the intervention is a nursing protocol for aspiration pneumonia prevention, not a drug-containing intervention. Therefore, it does not meet the criterion for a drug-containing trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Longitudinal Correlational Study of Psychological Resilience, Depression Disorder, and Brain Functional-Structural Hybrid Connectome in Breast Cancer. PMID 40226657 · Depress Anxiety · 2024 The study is a correlational investigation of psychological resilience and brain connectome in relation to depression disorder in breast cancer patients. It is part of a larger randomized trial (BRBC), but this specific analysis does not test a drug intervention, does not report an oncology-specific time-to-event efficacy endpoint (OS, PFS, etc.), and is a secondary/observational correlative study, not a primary therapeutic result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours. PMID 39886141 · BMJ Oncol · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Shenqi injection plus probiotics improves nutritional status in patients with gastric cancer after partial gastrectomy. PMID 39799437 · Pak J Pharm Sci · 2024 The record describes a randomized, human, oncology trial with a drug intervention, but the abstract does not explicitly confirm the trial phase (e.g., Phase III/IIIb or Phase II/III) or specify a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with formal Kaplan-Meier or HR results. The mention of 'prognostic survival rate' is vague and insufficient to establish a clear, formal time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center's experience. PMID 39777347 · Front Oncol · 2024 The record is excluded because it is a single-center subset analysis of a larger trial, not the original formal result of the Phase III/IIIb or Phase II/III randomized trial. The trial phase is also not explicitly confirmed in the metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic factors for overall survival in elderly patients with glioblastoma: Analysis of the pooled NOA-08 and Nordic trials with the CCTG-EORTC (CE.6) trial. PMID 39759261 · Neurooncol Adv · 2024 The record is a pooled analysis of three original randomized trials (NORDIC, NOA-08, CE.6). While it analyzes data from eligible trials, it is not the original formal-result report of a single Phase III/IIIb or Phase II/III randomized trial. The analysis itself is a secondary, prognostic study. Therefore, it does not meet the criterion for being an 'original formal-result report'. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cardiopulmonary Protection of Modified Remote Ischemic Preconditioning in Mitral Valve Replacement Surgery: A Randomized Controlled Trial. PMID 39742012 · Cardiovasc Ther · 2024 The study is a randomized controlled trial in human patients with a primary endpoint of serum cardiac troponin I concentration at specific postoperative time points, which is a biomarker, not a time-to-event efficacy endpoint. The intervention is a non-drug procedural intervention (remote ischemic preconditioning). While the publication types list Phase II and Phase III, the context is non-oncology cardiac surgery. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of the Acti-Pair programme on physical activity in patients with prostate cancer: protocol of the Acti-Pair 2 stepped-wedge cluster randomised trial. PMID 39717077 · BMJ Open Sport Exerc Med · 2024 The record is a protocol for a non-drug-only intervention (physical activity programme) and does not contain results. It is excluded because it is a protocol without results, the intervention lacks a drug component, and it does not target a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer. PMID 39711967 · Front Oncol · 2024 The trial is an oncology, human, randomized, phase 3 study with a drug intervention reporting primary results. However, it is ineligible because the primary/key secondary endpoint is pathological complete response (pCR), which is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) and there is no mention of Kaplan-Meier analysis or hazard ratios for survival or progression. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China. PMID 39711961 · Front Oncol · 2024 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results. PMID 39664679 · Neurooncol Adv · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Intraoral appliance treatment modulates inflammatory markers and oxidative damage in elderly with sleep apnea. PMID 39661789 · Braz Oral Res · 2024 The study is a randomized trial but does not meet the required oncology domain. It investigates obstructive sleep apnea (non-malignant), uses a device intervention (intraoral appliance, not a drug), and reports biomarker/clinical outcome endpoints (AHI, ODI, inflammatory markers) rather than a time-to-event efficacy endpoint such as OS, PFS, or DFS. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Adjuvant osimertinib therapy guided by ctDNA-assessed MRD in resected EGFR-mutated stage IA-IIA non-small-cell lung cancer: a randomized clinical trial study protocol. PMID 39659920 · Am J Cancer Res · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of anti-angiogenic drugs combined with chemotherapy in the treatment of platinum-sensitive/resistant ovarian cancer: a meta-analysis with trial sequential analysis of randomized controlled trials. PMID 39640492 · Front Pharmacol · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A non-inferiority, phase III trial of gemcitabine plus capecitabine versus gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer. PMID 39634173 · Ther Adv Med Oncol · 2024 The record explicitly describes a Phase III, randomized trial in human oncology (advanced triple-negative breast cancer) with a primary time-to-event endpoint (PFS) and a key secondary endpoint (OS). Both arms contain drug interventions (gemcitabine+capecitabine vs gemcitabine+carboplatin). The abstract provides formal results including hazard ratio and median survival times, confirming it is an original result report. No exclusion criteria apply. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 3 Figure · 14 Panel · risk unclear |
| Methodological insights from the EPISTOP trial to designing clinical trials in rare diseases-A secondary analysis of a randomized clinical trial. PMID 39625912 · PLoS One · 2024 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Preserving circumflex iliac lymph nodes to reduce the incidence of lower limb lymphedema following lymphadenectomy in cervical and endometrial cancers: A prospective randomized controlled trial. PMID 39621645 · PLoS One · 2024 The study is an oncology randomized trial with a time-to-event primary endpoint, but it does not involve a drug-containing intervention, which is a required criterion for eligibility. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficiency and safety of Buzhong Tiaogan granule for treating the colorectal cancer patients with liver metastasis: study protocol for a multicenter randomized controlled trial. PMID 39618820 · Front Med (Lausanne) · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Financial incentives and motivational intervention to improve gastric cancer screening in China: a randomized controlled trial study protocol. PMID 39600351 · BMJ Surg Interv Health Technol · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Development and feasibility of an mHealth intervention for psychoeducational support of Nigerian women diagnosed with breast cancer undergoing chemotherapy: A pilot randomized controlled trial. PMID 39585879 · PLoS One · 2024 The study is a pilot randomized controlled trial assessing feasibility and acceptability of a psychoeducational mHealth intervention for breast cancer patients undergoing chemotherapy. It meets the oncology, human, randomized, and drug intervention criteria. However, it is a Phase II pilot/feasibility study, not a definitive Phase III/IIIb or Phase II/III trial. Most importantly, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary outcomes are feasibility metrics (consent, attrition, completion rates) and acceptability via qualitative interviews. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| COMPARISON OF THE OUTCOMES OF ENHANCED RECOVERY AFTER SURGERY (ERAS) VS CONVENTIONAL CARE IN ELECTIVE COLORECTAL SURGERY. PMID 39585252 · J Ayub Med Coll Abbottabad · 2024 The study is a randomized, human oncology trial reporting original results, but it is ineligible due to the absence of a drug-containing intervention and a primary time-to-event efficacy endpoint. The intervention is a perioperative care protocol (ERAS vs conventional), not a drug. The outcomes are surgical recovery metrics, not survival or progression endpoints. Phase is not specified. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of a metaverse multimodal rehabilitation intervention on quality of life and fear of recurrence in patients with colorectal cancer survivors: A randomized controlled study protocol. PMID 39564355 · Digit Health · 2024 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors. PMID 39563716 · Ther Adv Med Oncol · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer. PMID 39530624 · Future Oncol · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The intervention effect of psychological care combined with ondansetron, dexamethasone, and promethazine hydrochloride on chemotherapy in breast cancer surgical patients. PMID 39520157 · Technol Health Care · 2024 Eligibility requires a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) in a Phase III/IIIb or Phase II/III randomized trial. This study is randomized and includes a drug intervention, but it lacks any time-to-event endpoint and does not specify a Phase III/IIIb or Phase II/III design. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Cardiac health in breast cancer (CHiB): protocol for a single-centre, randomised controlled trial. PMID 39502580 · BMJ Open Sport Exerc Med · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparing Participation and Interim Effectiveness of Endoscopy and Biomarker-Based Screening for Gastric Cancer: A Cluster Randomized Controlled Trial. PMID 39440067 · J Cancer · 2024 The record describes a randomized trial comparing screening methods for gastric cancer, but it lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The phase is not explicitly confirmed as Phase III/IIIb or II/III. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effect of smoking status on immunotherapy for lung cancer: a systematic review and meta-analysis. PMID 39439965 · Front Oncol · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Proof-of-Concept of an Integrated Yoga and Psychological Intervention in Mitigating Distress Among Diverse Women With Gynecologic, Gastrointestinal, and Thoracic Cancers. PMID 39423043 · Integr Cancer Ther · 2024 The study is a proof-of-concept, single-arm trial of a yoga and psychological intervention for cancer distress. It is not randomized, does not involve a drug intervention, is not Phase III/IIIb or II/III, and does not use a time-to-event efficacy endpoint. Therefore, it does not meet the eligibility criteria for the Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Very early remission and increased apoptosis with the use of Pentoxifylline in children with acute lymphoblastic leukemia. PMID 39421449 · Front Oncol · 2024 The study is an original randomized trial of a drug in oncology with a time-to-event efficacy endpoint (OS). However, the abstract does not explicitly state that it is a Phase III/IIIb or Phase II/III trial. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit phase information in the provided metadata, the phase criterion cannot be established, making the record ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association between female infertility and stroke mortality: evidence from the PLCO cancer screening trial. PMID 39381444 · Front Endocrinol (Lausanne) · 2024 The record describes an observational epidemiological study on non-cancer mortality (stroke) using data from a cancer screening trial. It is not an oncology clinical trial, lacks a drug intervention, and its endpoint is not an oncologic efficacy measure. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Exploring non-surgical alternatives for low to intermediate-grade in situ ductal carcinoma of the breast using vacuum-assisted excision: the VACIS protocol. PMID 39380737 · Front Med (Lausanne) · 2024 The record is a protocol for a randomized trial investigating a surgical/biopsy procedure for breast DCIS, not a results report. It lacks a drug intervention and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials. PMID 39376601 · Front Pharmacol · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| [Role of CAR-T in multiple myeloma and coordination between referring and treating centers]. PMID 39358259 · Rinsho Ketsueki · 2024 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
B
|
影子组漏检补回 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Effect of prehabilitation exercises on postoperative frailty in patients undergoing laparoscopic colorectal cancer surgery. PMID 39328202 · Front Oncol · 2024 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials. PMID 39315334 · Front Cell Infect Microbiol · 2024 The study is an oncology, human, randomized, Phase III trial with a drug (vaccine) intervention and an original result. However, it is excluded because the primary efficacy endpoint is not a time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. The endpoint is vaccine efficacy against CIN3/AIS, measured as a percentage reduction in case counts over a fixed follow-up period, not a time-to-event outcome. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends. PMID 39308935 · Cancer Manag Res · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies. PMID 39281971 · Ther Adv Med Oncol · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial. PMID 39250905 · Oncol Res Treat · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. PMID 39234256 · Front Immunol · 2024 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma. PMID 39229263 · Front Immunol · 2024 Study is non-randomized and retrospective, not a randomized trial, and does not establish definitive Phase III/IIIb or Phase II/III evidence as required. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Geriatric assessment for the practicing clinician: The why, what, and how. PMID 39207229 · CA Cancer J Clin · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The impact of telemonitoring on correct drug use, complications and quality of life among patients with multiple myeloma (ITUMM): A study protocol for an open-label, parallel-group, randomized controlled trial. PMID 39186588 · PLoS One · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer. PMID 39166278 · Technol Cancer Res Treat · 2024 The record is from a randomized trial with a drug intervention and reports primary/secondary time-to-event efficacy endpoints. However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the abstract or metadata, and the sample size is very small, precluding confirmation of it being a definitive-phase trial as required. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer. PMID 39155847 · Future Oncol · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |